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ABStrACt
We report the case of an 81-year-old patient with symptomatic 
severe aortic stenosis (AS) who developed refractory hemo-
dynamic instability and respiratory arrest during a diagnostic 
cardiac catheterization. The patient was submitted to a percu-
taneous balloon aortic valvuloplasty as a life saving procedure 
with subsequent hemodynamic improvement and clinical 
stabilization. The possibility of surgical treatment for AS was 
excluded due to the high surgical risk. Clinical follow-up of 
up to 7 months after the procedure demonstrated significant 
improvement in functional class and good exercise tolerance.
 
 
 
 
DESCrIPtOrS: Aortic valve stenosis. Shock, cardiogenic. Heart 
valve prosthesis implantation.
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rESUMO
Valvuloplastia Aórtica Percutânea como Medida 
Salvadora na Estenose Aórtica Crítica com 
Instabilidade Hemodinâmica
Relatamos o caso de uma paciente de 81 anos, com estenose 
aórtica (EA) grave sintomática, que, durante cateterismo cardíaco 
diagnóstico, evoluiu com instabilidade hemodinâmica refratária 
e posterior parada respiratória. Foi submetida à valvuloplastia 
aórtica percutânea por balão como medida salvadora, com 
subsequente melhora hemodinâmica e compensação clínica. 
A possibilidade de tratamento cirúrgico da EA foi descartada 
pelo alto risco cirúrgico. O acompanhamento clínico de até 
7 meses após o procedimento demonstrou melhora significativa 
da classe funcional e boa tolerância aos esforços.
DESCrItOrES: Estenose da valva aórtica. Choque cardiogênico. 
Implante de prótese de valva cardíaca.
S enile aortic stenosis (AS) is the obstruction of the left ventricular outflow tract due to valvular structure calcification, whether or not associated with aortic 
valve fusion. It is the most commonly acquired aortic 
valve disease, and is present in 4.5% of population older 
than 75 years.1 Surgical aortic valve replacement is the 
first-choice therapy for patients with severe AS, result-
ing in symptom relief and increased survival. However, 
due to the high surgical risk, approximately one-third 
of octogenarians with symptomatic AS are rejected 
for surgery.2 Percutaneous balloon aortic valvuloplasty 
(PBAV) is a procedure considered to be a bridge in 
hemodynamically unstable patients not capable of un-
dergoing surgical procedure. Due to the high incidence 
of restenosis and aortic regurgitation, it is currently in-
dicated only in exceptional circumstances, for instance, 
as a palliative measure or intermediate to a definitive 
treatment.3 Currently, percutaneous aortic valve implanta-
tion (PAVI) is an option for patients with high risk for 
conventional surgical treatment. Since 2002, from the 
initial experience by Cribier et al.,4 over 50,000 PAVI 
shave been performed with different devices.5
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The present study reports a case of an emergency 
PBAV performed due to the occurrence of severe and 
refractory hemodynamic instability during angiography 
procedure.
CASE REPORT
The patient was an 81-year-old female, with a 
known history of hypertension and dyslipidemia, with 
AS for five years, dyspnea on moderate exertion, and 
typical anginal chest pain. Approximately one year 
before, she experienced worsening of functional class, 
with dyspnea on mild exertion, syncope, and angina 
episodes. A transthoracic echocardiography performed 
in September 2012 demonstrated a tricuspid aortic valve 
with significant calcification, mean transvalvular gradi-
ent of 65  mmHg, peak velocity of 5.3 m/s, estimated 
valve area of 0.63 cm2, left ventricular ejection fraction 
(LVEF) of 55%, and interventricular septum of 15 mm, 
meeting the echocardiographic criteria for severe aortic 
stenosis (without aortic insufficiency) .
In October 2012, the patient underwent diagnostic 
cardiac catheterization for preoperative evaluation pur-
poses. During the examination, the patient developed 
refractory hemodynamic instability, acute respiratory 
failure, decreased level of consciousness, and subse-
quent respiratory arrest, requiring orotracheal intubation 
and high doses of vasoactive agents. Given the critical 
situation, with rapid clinical deterioration and need 
for increasingly higher doses of norepinephrine, it was 
decided to perform the PBAV promptly.
Procedure
The PBAV was performed through the right femoral 
artery. A 23 × 45 mm Aviator® Plus balloon (Cordis 
Corporation, Bridgewater, USA) was used, inflated 
once for less than 10 seconds (Figure 1), with the aid 
of rapid pacing with temporary transvenous pacemaker 
positioned in the right ventricle via the right femoral 
vein, for stable positioning of the balloon. An immediate 
decrease was observed in the aortic transvalvular sys-
tolic pressure gradient, from 180 mmHg to 120 mmHg 
(Table 1), with significant improvement in hemodynamic 
status and prompt norepinephrine weaning. The control 
angiogram showed only mild aortic valve regurgitation 
(Figure 2). Echocardiography was not available during 
or immediately after the procedure. The patient was 
then transferred to the intensive care unit, for clinical 
stability and decision-making on the future surgical 
treatment of the AS.
Clinical evolution
The post-procedural outcome was favorable, and 
the patient was extubated within 24 hours, with res-
toration of hemodynamic stability without vasoactive 
drugs. Echocardiogram performed at the bedside 48 
hours after PBAV maintained the criteria for severe 
AS, despite the clinical improvement (mean transval-
vular gradient of 48  mmHg; aortic valve area of 0.91 
cm2; LVEF 59%). Due to the risk surgical high (esti-
mated mortality according to the European System for 
Cardiac Operative Risk Evaluation [EuroSCORE II] of 
15.2% and a Society of Thoracic Surgeons [STS] risk 
score of 52.1%), as well as the difficulties to perform 
PAVI under the public health system, and considering 
the satisfactory progress after PBAV, it was decided to 
maintain the patient in clinical treatment.
The patient was discharged after ten days, in good 
general status and asymptomatic, with no complications 
from the procedure. She was referred to cardiologic 
clinical monitoring. Seven months after the procedure, 
the patient was asymptomatic from the cardiovascular 
perspective, without the occurrence of any adverse 
cardiac events, with good tolerance to exertion (func-
tional class I), and no change in AS classification at 
the echocardiography.
DISCUSSION
PBAV was developed as a non-surgical option in 
1980 for the treatment of patients with severe AS. It is 
a procedure in which one or more balloons are placed 
through the stenotic aortic valve and inflated in order to 
reduce lesion severity. It causes fractures in the calcium 
deposited in the valve leaflets, with enlargement of the 
aortic annulus and separation of commissures.6 Despite 
the considerable rates of possible complications (severe 
acute aortic regurgitation, vascular/hemorrhagic compli-
cations and access route-related complications, stroke, 
and death), the immediate results produce a moderate 
decrease in transvalvular gradients with symptomatic 
improvement, but only a small increase in valvular 
area, which determines high restenosis rates and poor 
medium- and long-term outcome.7
The PBAV technique has undergone improvements in 
last years, such as a decrease in the catheter diameter; 
more reliable balloons (smaller profile, and simpler 
and safer materials in the technical management); 
rapid ventricular rhythm established by a pacemaker, 
stabilizing the baloon in the aortic valve plane during 
dilation; and more appropriate guide wires (extra-stiff, 
super-stiff), among others. Currently, PBAV is strongly 
recommended as valve preparation for subsequent PAVI 
(pre-dilation), and has been increasingly used, in parallel 
with the bioprosthesis catheter-implantation technique.8
A patient with critical AS with acute heart failure 
or cardiogenic shock represents a therapeutic chal-
lenge, as this is a condition whose definitive treatment 
is complex and carries a high risk of death. PBAV is 
generally used in this context as a bridge to surgery; 
however, due to the modest increase in valve area and 
the reasonable complication rate, there is a limitation 
for its use, even in these patients.9 In 2008, the up-
dated guidelines of the American College of Cardiology/
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American Heart Association (ACC/AHA) for the man-
agement of valvular heart disease indicated that PBAV 
was a class IIb recommendation as palliative care or 
a bridge to surgery in unstable patients or those with 
severe comorbidities (and class III for its use as a rou-
tine alternative to surgical valve replacement).10 With 
similar recommendations, the Brazilian guidelines on 
valve disease, from 2011, added the indication of class 
IIa for PBAV in hemodynamically unstable patients and 
momentary incapacity to undergo PAVI, maintaining 
the IIb indication when treatment is considered pal-
liative.11 In practice, PBAV has restricted use and does 
not modify the natural history of the disease, as well 
as resulting in only temporary symptom improvement, 
thus requiring a subsequent final treatment.
In this case, PAVI bioprosthesis was considered as 
the most suitable alternative for definitive treatment of 
the patient, which has been approved for use in Brazil 
by the National Health Surveillance Agency (Agência 
Nacional de Vigilância Sanitária – ANVISA) since 2008. 
According to the Placement of Aortic Transcatheter 
Figure 2. Control aortography in left anterior oblique projection, show-
ing only mild aortic regurgitation.
Figure 1 – Emergency percutaneous balloon aortic valvuloplasty: (A) passage of the extra-stiff guidewire through the aortic valve plane to deliver 
and position the balloon, (B) 23 × 45 mm Aviator® Plus balloon inflated once for less than 10 seconds with the aid of rapid pacing with temporary 
transvenous pacemaker, positioned in the right ventricle through the right femoral vein for stable placement of the balloon.
tABLE 1  
Invasive measurements of cavity pressures  
before and immediately after percutaneous  
balloon aortic valvuloplasty
Left 
ventricle 
(mmHg)
Aorta 
(mmHg)
Peak transvalvular 
systolic gradient 
(mmHg)
Pre-procedure 270 90 180
Post-procedure 210 90 120
A B
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Valves Trial (PARTNER),12 an important randomized clini-
cal trial conducted at 21 centers in the United States, 
Canada, and Germany, it was observed that mortality, 
both early and late, was dramatically reduced when 
patients were treated with PAVI, in comparison with 
medical treatment eventually associated with PBAV. 
Furthermore, in the cases considered to be periopera-
tive high-risk, mortality was equivalent when PAVI was 
compared with surgical treatment, demonstrating that 
percutaneous implantation of aortic bioprosthesis is a 
safe therapeutic option for this population.13
To date, PAVI is a therapeutic modality that is not 
available in the public healthcare system in Brazil. Thus, 
although scarcely recommended and even discredited 
by many, PBAV can improve the quality of life of many 
patients, and it is a viable alternative in the search for 
health, as cardiologists wait for the regulatory authori-
ties to approve the inclusion of PAVI in the country’s 
public and private health systems.
This case report illustrates the actions of the in-
terventional cardiologist during a life-saving measure. 
The use of PBAV in severe AS was indicated on an 
emergency basis, due to cardiogenic shock, imminent 
risk of death, and high surgical risk.
The procedure was able to promote subsequent 
improvement in hemodynamics and clinical com-
pensation. The authors believe that PBAV should be 
considered a valid option, whether or not associated 
with subsequent percutaneous or surgical aortic valve 
implantation, especially in unstable patients in critical 
condition. In the context of PAVI use, it can be stated 
that PBAV may be once again considered in clinical 
practice.
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